A landmark follow-up study found that heart attack survivors who receive implanted cardioverter defibrillators (ICDs) live longer the longer they have them, according to the results of alate-breaking clinical trail presented today at the annual Scientific Sessions of the Heart Rhythm Society.
ICDs are devices designed to correct arrhythmias, electrical malfunctions that throw the heart out of rhythm and cause many of the sudden cardiac deaths each year in the United States. Most fatal arrhythmias in the aging are caused by scar tissue left behind by heart attacks that interferes with the heart's electrical system.
The study that first tested the effectiveness of ICDs, the 2002 MADIT II trial (Multicenter Automatic Defibrillator Implantation Trial II), changed medical guidelines nationwide and made thousands of heart attack survivors eligible for ICD therapy. Led by Arthur Moss, M.D., professor of Medicine in the Department of Medicine at the University of Rochester Medical Center, the study found that the devices reduced risk of sudden cardiac death by 31 percent in heart attack survivors. At the same time, the ICD therapy could extend the average patient's life by about two months over a follow-up period that averaged about 2 years per patient. While that survival benefit was meaningful to patients, some critics argued that it did not make sense for the healthcare system to pay $25,000 for a device that provided a modest extension of life in patients with chronic cardiac disease.